Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is expected to perform well in the future due to its pioneering program, detalimogene voraplasmid, for patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program has shown competitive efficacy and potential best-in-class tolerability in the ongoing LEGEND Phase 2 trial, with a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients. Additionally, enGene's Dually Derivatized Oligochitosan (DDX) platform boasts ease of use and no special handling or storage requirements, making it a potential first-choice treatment for community urologists who treat the majority of NMIBC patients. This could lead to a significant increase in the company's valuation and future success in addressing other malignancies.

Bears say

enGene Therapeutics is facing multiple challenges as it moves towards the commercialization of its lead product candidate, detalimogene, which is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial for bladder cancer. While bladder cancer is a high clinical burden disease with a significant unmet need for effective treatments, enGene's current financials and lack of approved products put it at a disadvantage compared to its competitors in the gene therapy space. Furthermore, the company's success will heavily depend on the success of the ongoing trial and the timely approval and launch of detalimogene, which may face challenges in a competitive market with multiple approved options.

ENGN has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 6 analysts, ENGN has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.